Page last updated: 2024-09-04

cdri 85-287 and Breast Neoplasms

cdri 85-287 has been researched along with Breast Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chandra, V; Debnath, U; Dwivedi, A; Hajela, K; Konwar, R; Kumar, S; Manohar, M; Megu, K; Prabhakar, YS; Roy, BG; Saini, KS; Saxena, R	1
Blesson, CS; Chandra, V; Dwivedi, A; Fatima, I; Hajela, K; Hussain, MK; Kharkwal, G; Roy, BG; Saxena, R	1

Other Studies

2 other study(ies) available for cdri 85-287 and Breast Neoplasms

Article	Year
Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways. PloS one, 2013, Volume: 8, Issue:6 Topics: Aged; Animals; Antineoplastic Agents; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Middle Aged; Molecular Docking Simulation; Piperidines; Signal Transduction; Xenograft Model Antitumor Assays	2013
Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft. Steroids, 2013, Volume: 78, Issue:11 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Binding, Competitive; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin D1; Epidermal Growth Factor; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Mice; Phosphatidylinositol 3-Kinases; Piperidines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Transcription Factor AP-1; Transcriptional Activation; Xenograft Model Antitumor Assays	2013

Article

Year

Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways.

PloS one, 2013, Volume: 8, Issue:6

Topics: Aged; Animals; Antineoplastic Agents; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Middle Aged; Molecular Docking Simulation; Piperidines; Signal Transduction; Xenograft Model Antitumor Assays

2013

Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.

Steroids, 2013, Volume: 78, Issue:11

Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Binding, Competitive; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin D1; Epidermal Growth Factor; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Mice; Phosphatidylinositol 3-Kinases; Piperidines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Transcription Factor AP-1; Transcriptional Activation; Xenograft Model Antitumor Assays

2013